KOSDAQBiotech & Pharma245620

Eone Diagnomics Genome Center

₩741 0.00%2026-11-18 close
Market Cap
₩167.1B
Turnover
₩0
Volume
0 shares
Shares out.
230M
PER
2.9×
PBR
6.8×
EPS
₩259
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Genome Diagnostics Firm in Restructuring as Sales Shrink

Sales fell from KRW 94.2 billion in 2022 to KRW 7.89 billion in 2025, and after the 2025 swing to net profit attributable to controlling shareholders, net losses returned in the second and third quarters of 2026, leaving the earnings direction unsettled.

  1. 1

    Sales declined for three consecutive years from 2023 to 2025, and the 2025 figure of KRW 7.89 billion was down 74.5% from the prior year.

  2. 2

    The company posted operating losses in each of the four years from 2022 to 2025, and the 2025 operating loss of KRW 1.6 billion was narrower, with an operating margin of -20.2%.

  3. 3

    Net profit attributable to controlling shareholders turned positive at KRW 28.2 billion in 2025, a figure far larger than the operating losses, which suggests non-operating items had a major effect.

  4. 4

    The restructuring process began with a court decision in May 2024 and was followed by restructuring-plan approvals in March 2026, a change in the largest shareholder in April 2026, and a change of CEO in June 2026.

  5. 5

    The next checkpoints are how the private convertible bond with a maturity of December 10, 2026 in the Q1 2025 report was settled, and the 2026 annual report.

02

Business structure

EDGC (Eone Diagnomics Genome Center) was founded in 2013 as a genome-analysis-based diagnostics and services company and listed on KOSDAQ in 2018 under the technology special listing system.

Its core business is next-generation sequencing (NGS)-based testing services, and according to the JobKorea company profile, NGS-related sales accounted for 77% to 78% as of March 2026.

The same source shows GSA-related sales at 10% to 11% and other genome services at 10% to 12%, but the two tallies use different category layouts, so the detailed shares should be treated as reference only.

Key products include non-invasive prenatal testing, newborn genome screening and the OncoCatch liquid biopsy cancer diagnostic service. The company also runs consumer genetic test brands such as bebegene, gene2me and myeyegene.

At its 10th anniversary event in 2023, the company said its services were available in more than 30 countries and that it had accumulated more than 500,000 clinical test and research records.

It also promoted AI genome businesses such as GeniBot, a generative-AI genetic chatbot, and Yougenity, a genome-based social network service. A Maeil Business Newspaper report in August 2024 described the company as a leader in Korea's genome analysis field.

Unlike listed peers in the biopharma sector that center on drug pipelines or product sales, EDGC's structure is built around per-test services and data. As of June 30, 2026, JobKorea listed 59 employees.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.8B-₩400M−23.2%
2025Q4₩1.7B-₩400M−21.2%
2026Q1₩1.6B-₩1.3B−81.4%
2026Q2₩1.2B-₩700M−58.5%
2026Q3₩1.3B-₩700M−55.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩94.2B-₩9.5B-₩29.9B−10.1%−93.5%484.8%
2023₩88.5B-₩9.4B-₩33B−10.6%−86.4%343.7%
2024₩30.9B-₩12.6B-₩95.2B−40.8%—−294.5%
2025₩7.9B-₩1.6B₩28.2B−20.2%—−295.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales fell from KRW 94.2 billion in 2022 to KRW 88.5 billion in 2023 (down 6.1% year on year), KRW 30.9 billion in 2024 (down 65.0%) and KRW 7.89 billion in 2025 (down 74.5%). Sales declined for three consecutive years from 2023 to 2025, and the 2025 figure is less than one-tenth of the 2022 level.

Operating losses were KRW 9.52 billion in 2022, KRW 9.36 billion in 2023, KRW 12.6 billion in 2024 and KRW 1.6 billion in 2025, a deficit in each of the four years, with operating margins of -10.1%, -10.6%, -40.8% and -20.2%.

The 2024 operating loss was the largest of the four years, while the 2025 loss narrowed even though sales fell 74.5% in the same year.

By segment, a Korea Ratings assessment dated April 2024 showed the genome analysis services operating loss at about KRW 7.4 billion and the medical device distribution loss at about KRW 3.3 billion in 2022, and about KRW 5.5 billion and KRW 3.2 billion in 2023.

The same assessment linked the 2021 shift of the medical device distribution business into losses to lower prices for diagnostic kits. Operating cash flow moved from -KRW 10.9 billion in 2022 and -KRW 14 billion in 2023 to KRW 6.69 billion in 2024 and KRW 3.5 billion in 2025, turning positive.

Net profit attributable to controlling shareholders was a loss of KRW 29.9 billion in 2022, a loss of KRW 33 billion in 2023 and a loss of KRW 95.2 billion in 2024, before turning to KRW 28.2 billion in 2025.

On a quarterly basis, sales moved from KRW 1.79 billion in the third quarter of 2025 to KRW 1.26 billion in the third quarter of 2026, down 29.5% year on year. The first-quarter 2026 operating loss of KRW 1.3 billion was the largest among the last five quarters.

Net profit attributable to controlling shareholders of KRW 20.2 billion in the fourth quarter of 2025 and KRW 24.7 billion in the first quarter of 2026 were far larger than the operating losses of KRW 362 million and KRW 1.3 billion in those quarters, which points to a large effect from non-operating items.

The sum over the latest four quarters is KRW 42.8 billion, but the second and third quarters of 2026 returned to losses of KRW 730 million and KRW 1.42 billion.

05

Industry analysis

EDGC has been cited as one of the leading companies in Korea's genome analysis market. A Maeil Business Newspaper report in August 2024 said strategic investors were interested in this position and in the likelihood of a resumption of trading once going-concern uncertainty was resolved.

In testing areas introduced to clinical settings, such as non-invasive prenatal testing and liquid biopsy, test pricing and hospital adoption largely determine sales.

The 2021 decline in diagnostic kit prices, which pushed the medical device distribution business into losses, shows how product price changes directly affect results. The company has also built overseas partnerships and has run services in areas such as Thailand and China.

Its data-driven AI business has been presented as a new growth axis, but it is not yet clearly visible in recent quarterly sales.

Compared with larger listed peers that grow through production capacity and product sales, EDGC's service-based structure differs in revenue recognition and business model, making direct comparison difficult.

Its position in the sector therefore combines a technology-based standing among Korean leaders with a shrinking sales trend.

06

Outlook

The company's stated goal is to resolve going-concern uncertainty and resume trading. In 2025 the company said it would proceed with the remaining restructuring steps without delay in order to resume trading.

The sale process began with the appointment of a sales adviser in August 2024, but DealSite reported that no buyer was found in public bidding rounds held in August and October of that year.

In August 2025 a stalking horse agreement was signed with a prospective acquirer, and in September 2025 the final acquirer was confirmed.

However, because the October payment of the balance required by the exchange was not met, the Korea Exchange resolved on November 19, 2025 to delist the company, and the company reportedly applied to the court for a provisional injunction to suspend the delisting.

In March 2026, approvals were recorded for repayment of restructuring claims, debt-to-equity conversion, a share consolidation and a rights offering under the restructuring plan.

In April 2026 the largest shareholder changed to Haemilly, and in June 2026 the CEO post changed from Min Seob Lee to Bong Jo Kim and Min Chul Ma. A private convertible bond listed in the Q1 2025 report carried a maturity of December 10, 2026, so how that debt was settled after plan approval is a checkpoint.

The business direction and financing plans of the new management team are expected to become clearer in upcoming periodic reports and disclosures.

07

Valuation

PER
2.9×
PBR
6.8×
ROE
309.6%
EPS
₩259
BPS
₩109
Dividend per share
₩0

Valuation is more readily interpreted on an asset basis than on an earnings basis. The price-to-book ratio sits in a range with a large premium over net asset value, meaning the market is attaching a high value relative to book equity.

A price-to-earnings comparison can be built on the KRW 42.8 billion sum of net profit attributable to controlling shareholders over the latest four quarters, but most of that sum came from profits in the fourth quarter of 2025 and the first quarter of 2026, which appear to reflect non-operating items.

Earnings-based multiples therefore need to be read together with the composition of those profitable quarters. Net losses continued in the second and third quarters of 2026, so using only the profitable quarters as a base could diverge from the direction of earnings.

The dividend yield is effectively nil and sits below the sector average. Comparison with historical trading multiple bands will carry more meaning once the restructuring is settled and periodic results have built up a steadier record.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Progress in restructuring and possible capital structure cleanup

Approvals were recorded in March 2026 for repayment of restructuring claims, debt-to-equity conversion and a share consolidation under the restructuring plan. Once the process is completed, the company's stated aim of resolving going-concern uncertainty and resuming trading could become achievable.

Total liabilities were KRW 66.5 billion and total equity KRW 22.5 billion at year-end 2025, and how the capital structure changes in the next periodic report is the point to check.

Positive operating cash flow and the 2025 profit swing

Operating cash flow shifted from outflows in 2022 and 2023 to inflows in 2024 and 2025, and whether this continues is the next point to check. Over the same period, net profit attributable to controlling shareholders turned positive at KRW 28.2 billion in 2025.

The 2025 operating loss of KRW 1.6 billion remains, so the core business has not yet returned to operating profit.

Genome data assets and the foundation for an AI strategy

At its 10th anniversary event in 2023, the company said it had accumulated more than 500,000 clinical test and research records. It plans to use these to develop biomarkers and AI algorithms for diagnostics and drug development. An August 2024 report also cited the company's standing as a leader in Korea's genome analysis field.

09

Bear factors

Sales decline continuing for three consecutive years

Sales fell from KRW 94.2 billion in 2022 to KRW 7.89 billion in 2025, declining for three consecutive years from 2023. Third-quarter 2026 sales of KRW 1.26 billion rose 3.3% from the prior quarter but fell 29.5% from the same quarter a year earlier. A clear recovery in quarterly sales is not yet visible.

Continuing operating losses and quality of earnings

The company recorded operating losses in each of the four years from 2022 to 2025 and in each of the five quarters from the third quarter of 2025 through the third quarter of 2026.

Net profit attributable to controlling shareholders was concentrated in the fourth quarter of 2025 and the first quarter of 2026, and net losses reappeared from the second quarter of 2026. If the profits came from non-operating items, the underlying earnings strength looks limited.

Debt relative to equity and financing burden

Total liabilities of KRW 66.5 billion at year-end 2025 far exceed total equity of KRW 22.5 billion. The Q1 2025 report listed several private convertible bonds with maturities running from late 2026 into 2027, so repayment pressure remains. Financing options may vary depending on the listing status and the outcome of the restructuring.

10

Risk factors

Listing eligibility and going-concern risk

A disclaimer of opinion on the 2023 financial statements triggered a formal delisting ground, and on November 19, 2025 the Korea Exchange resolved to delist the company. The company reportedly applied for a provisional injunction.

Listing status and the timing of resumed trading are the largest uncertainties and should be monitored through audit opinions in periodic reports.

Financial structure and accumulated operating losses

Summed across 2022 to 2025, operating losses total about KRW 33.1 billion. With total liabilities of KRW 66.5 billion against total equity of KRW 22.5 billion at year-end 2025, further losses could erode the equity cushion quickly.

Operating cash flow turned positive, but at KRW 3.5 billion in 2025 the room to absorb debt repayments is limited.

Business concentration and pricing risk

According to the JobKorea company profile, NGS-related sales made up 77% to 78% of revenue as of March 2026, so the business is concentrated in one testing area. In 2021, lower diagnostic kit prices pushed the medical device distribution business into losses. Lower test fees or product prices could delay a sales recovery, so changes in the business mix matter.

11

What to watch next

  1. December 10, 2026

    This is the maturity date of the 8th private convertible bond listed in the Q1 2025 report. The next check is how the debt was repaid or converted after plan approval, as shown in later periodic report notes.

  2. March 31, 2027 (statutory filing deadline)

    This is the expected filing of the 2026 annual report. The key items are full-year 2026 sales and operating results, fourth-quarter performance and the external audit opinion, including any going-concern language.

  3. May 15, 2027 (statutory deadline)

    This is the statutory deadline for the Q1 2027 quarterly report. The points to check are the quarter-on-quarter sales trend, the operating loss trend, and the share of non-operating items in net profit attributable to controlling shareholders.

12

Overall view

EDGC's sales fell from KRW 94.2 billion in 2022 to KRW 7.89 billion in 2025, and operating losses continued in each of the four years from 2022 to 2025. On the other side, net profit attributable to controlling shareholders turned to KRW 28.2 billion in 2025, and operating cash flow has been positive since 2024.

However, that profit is large relative to the operating losses, which suggests non-operating items played a bigger role than core business improvement. Net losses returned in the second and third quarters of 2026, and third-quarter sales were down 29.5% year on year.

Listing status has been tied directly to the restructuring outcome since the 2024 audit disclaimer and the 2025 delisting resolution.

The March 2026 approvals, the April 2026 change in the largest shareholder and the June 2026 change of CEO mean that the effect of the new management on business direction is the next point to verify. The most direct check is the 2026 annual report, covering full-year sales, operating results and the audit opinion.

Growth arguments rest on genome data assets and an AI strategy, but these are not yet clearly visible in periodic results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. innoforest.co.kr
  2. saramin.co.kr
  3. newsfc.co.kr
  4. dailymedi.com
  5. kisrating.com
  6. pharmnews.com
  7. news.nate.com
  8. nongaek.com
  9. dealsite.co.kr
  10. biz.heraldcorp.com
  11. kr.investing.com
  12. jobkorea.co.kr
  13. kr.investing.com
  14. jobkorea.co.kr
  15. catch.co.kr
  16. investing.com
  17. kind.krx.co.kr
  18. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis